Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM™ Subcutaneous Implantable Defibrillator and EMPOWER™ Leadless Pacemaker
/PRNewswire/ Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the.
MARLBOROUGH, Mass., April 24, 2024 /PRNewswire/ Boston Scientific Corporation generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis,.
MARLBOROUGH, Mass., April 8, 2024 /PRNewswire/ Boston Scientific Corporation has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module when it is used to visualize and track the.
Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.